Esperion Therapeutics ESPR Deferred Tax Liabilities, Gross
Deferred Tax Liabilities, Gross at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilities.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's deferred tax liabilities, gross.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's deferred tax liabilities, gross?
- Esperion Therapeutics (ESPR) reported deferred tax liabilities, gross of $787K in Q4 2025.
- How has Esperion Therapeutics's deferred tax liabilities, gross changed year-over-year?
- Esperion Therapeutics's deferred tax liabilities, gross decreased by 48.3% year-over-year, from $1.52M to $787K.
- What is the long-term trend for Esperion Therapeutics's deferred tax liabilities, gross?
- Over 5 years (2020 to 2025), Esperion Therapeutics's deferred tax liabilities, gross has grown at a -49.9% compound annual growth rate (CAGR), from $24.95M to $787K.